SCHEMBL8907760

SCHEMBL8907760

O=C(O)CNC(=O)c1ccc(Br)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.67
MAPT P10636 1/20 0.67
HIF1A Q16665 1/20 0.67
SLC22A6 Q4U2R8 1/20 0.67
SLC22A8 Q8TCC7 1/20 0.67
CA1 P00915 2/20 0.59
CA2 P00918 2/20 0.59
OGG1 O15527 1/20 0.59
ATM Q13315 1/20 0.56
USP5 P45974 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
HSP90AA1 P07900 1/20 0.53
NFKB1 P19838 1/20 0.53
CASP3 P42574 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25362488 0.90 SMN1; SMN2 (0.64) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL11107537 0.89 KDM4E (0.80) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL16898615 0.83 OGG1 (0.63) CA1CA2OGG1SMN1; SMN2NPC1
SCHEMBL24224263 0.83 KDM4E (0.71) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL4928682 0.82 MMP1 (0.61) OGG1SMN1; SMN2KMT2AHPGDMEN1
SCHEMBL25316335 0.82 OGG1 (0.57) OGG1SMN1; SMN2NPC1RAB9AHSP90AA1
SCHEMBL26568488 0.82 OGG1 (0.57) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL936016 0.82 HIF1A (0.69) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL22030672 0.81 GAA (0.68) KDM4EMAPTHIF1ASLC22A6SLC22A8
Hippuric Acid SCHEMBL7486 0.81 GAA (0.68) KDM4EMAPTHIF1ASLC22A6SLC22A8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
EP-3341007-B1 MALT1 INHIBITORS AND USES THEREOF UNIV CORNELL (US) 2020-12-23 EP disclosed
US-5609848-A Radiohalogenated small molecules for protein labeling NEORX CORPORATION (US) 1997-03-11 US disclosed
US-5213787-A RADIOHALOGENATED SMALL MOLECULES FOR PROTEIN LABELING NEORX CORPORATION (US) 1993-05-25 US disclosed
US-5045303-A Radiohalogenated small molecules for protein labeling NEORX CORPORATION (US) 1991-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 KDM4E 4647/4885MAPT 1464/4885HIF1A 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.